CA
ADPT icon

Calton & Associates’s Adaptive Biotechnologies ADPT Stock Holding History

Calton & Associates’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,781
Closed -$117K – 191
2023
Q4 		$117K Buy
+23,781
New +$109K 0.05% 234
2023
Q3 		– Sell
-14,020
Closed -$94.1K – 103
2023
Q2 		$94.1K Sell
14,020
-533
-4% -$3.96K 0.04% 206
2023
Q1 		$129K Buy
14,553
+268
+2% +$2.36K 0.06% 221
2022
Q4 		$109K Buy
14,285
+3,863
+37% +$30.1K 0.04% 270
2022
Q3 		$74K Sell
10,422
-271
-3% -$2.55K 0.04% 205
2022
Q2 		$86K Sell
10,693
-662
-6% -$5.82K 0.05% 229
2022
Q1 		$157K Buy
+11,355
New +$179K 0.05% 336
2021
Q1 		– Sell
-3,734
Closed -$221K – 398
2020
Q4 		$221K Buy
+3,734
New +$193K 0.04% 344

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Calton & Associates's ADPT Position: Q1 2024 in Review

Calton & Associates sold out of Adaptive Biotechnologies (ADPT) in Q1 2024, closing a stake of 23,781 shares — an estimated $117K sold.

Calton & Associates first reported a position in ADPT in Q4 2020 and held it in 8 quarters. The position peaked at $221K in Q4 2020. 190 funds tracked by Wall St. Rank hold ADPT as of Q1 2024.

  • Calton & Associates reported no remaining Adaptive Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • Calton & Associates sold 23,781 Adaptive Biotechnologies shares in Q1 2024, an estimated $117K.
  • Calton & Associates first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 8 quarters.
  • Calton & Associates's Adaptive Biotechnologies position peaked at $221K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2024.

Based on Calton & Associates's 13F filing for Q1 2024, filed 16 Apr 2024.